Tag Archives: FiercePharma

Wondering why some of your Pharma shares keep going up? Thank Trump’s tax “reform;” no, really.

The News: The drug industry has taken heat from patient advocates and a US senator for handing out its tax savings to shareholders instead of using its windfall to help patients… Read more »

Doctors reliance on pharmas increasing, while general public trusts supermarkets more. What’s wrong with this picture?

The News: When it comes to pharma partners, doctors prefer quality digital content, according to a new report. While that comes as no surprise and makes sense, new research shows… Read more »

Pfizer, Merck’s Bavencio flop illustrative of shattered Pharma model. Is industry’s collapse just around the corner?

The News: Pfizer Inc. (NYC) and its German part­ner Merck KGaA (Darmstadt) have run into a brick wall in their race to ex­pand the mar­ket for their PD-L1 check­point inhibitor Baven­cio… Read more »

Alarming study concludes most new, pricey cancer drugs don’t work; why are we just hearing about this?

The News: Researchers said only half of the cancer drugs approved by European regulators in the past few years have shown to help patients. Many of the drugs were approved… Read more »

Catabasis soars on fresh Duchenne trial data, proving biotech melt-up still in progress; but for how much longer?

The News: Recuperating from a trial flop involving its lead drug for Duchenne muscular dystrophy, Catabasis Pharmaceuticals Inc. (Cambridge MA) is charging ahead with a late-stage study, hyping new data… Read more »

Senators seek probe of Allergan’s patent sale to Mohawk Tribe; could Tesla do the same with its battery patents?

The News: Four senators are demanding an investigation of Allergan PLC’s (Dublin IRL) first-of-a-kind patent deal with the Saint Regis Mohawk Tribe, alleging the move to protect Restasis is another… Read more »

Amgen, Allergan get nod for Avastin biosim; FDA’s Gottlieb making good on vow to hasten generic approvals, catch the EU.

The News: Amgen Inc. (Thousand Oaks CA) and Allergan PLC (Dublin IRL) said Thursday (September 14, 2017) that the Food and Drug Administration has approved their biosimilar version of Roche… Read more »

Slumbering giant Lilly to cut more jobs, take a $1.2-billion hit to bolster R&D pipeline.

The News: Eli Lilly & Co. (Indianapolis IN) last week said it would lay off about 8% of its employees as the drugmaker, which has suffered setbacks over the past… Read more »

Novartis CEO Jimenez is stepping down; does successor Narasimhan have the right stuff to take the reins in 2018?

The News: Swiss pharmaceuticals titan Novartis AG (Basel) will get a new chief executive in 2018–Dr. Vasant Narasimhan (pdf)–after Joseph Jimenez proclaimed his upcoming retirement effective in February. Jimenez has… Read more »

Winners outpace losers in wild week for healthcare stocks; my picks and pans.

Leading the largest pack of winners in quite a while, XOMA Corp. (Nasdaq:XOMA) soared $5.64, or 48% over the week, to $11.10, after the company revealed an agreement to out-license… Read more »